Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
PHASE3
Efficacy and safety of BI 1356 compared to placebo in patients with type 2 ...
Status
Completed
Location
1218.35.10002 Boehringer Ingelheim Investigational Site
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
PHASE3
The primary objective is to demonstrate superior glycaemic control (HbA1c r...
Status
Completed
Location
1264.3.01026 Boehringer Ingelheim Investigational Site